NDMA, or N-nitrosodimethylamine, is a chemical contaminant that gained widespread attention after it was found in several common medications, including the heartburn drug Zantac (ranitidine), blood pressure medications like valsartan, and some forms of metformin. It is classified as a probable human carcinogen by the EPA, the International Agency for Research on Cancer, and the U.S. Department of Health and Human Services. The concern isn’t that NDMA is a drug itself, but that it can show up as an unwanted impurity inside drugs people take every day.
What NDMA Actually Is
NDMA is a small organic molecule that forms through both industrial and natural chemical processes. It was once used in the production of liquid rocket fuel, lubricant additives, and rubber softeners, but those uses were largely abandoned once its cancer-causing potential became clear. Today, most human exposure comes through food and water: smoked or cured meats, beer and whiskey (where it forms during processing), chlorine-treated drinking water, and even cigarette smoke all contain trace amounts.
In other words, NDMA isn’t something that only exists in contaminated pills. Your body encounters small amounts of it regularly. The issue with medications is one of dose and duration. Someone taking a daily pill for years could accumulate far more NDMA than they would from the occasional slice of bacon, especially if the contamination levels in that pill exceeded safe thresholds.
How NDMA Ends Up in Medications
NDMA doesn’t get added to drugs on purpose. It forms as an unintended byproduct, and the way it forms differs depending on the medication. Three ingredients are needed for NDMA to appear: a nitrogen-containing compound (which many drug molecules naturally have), a nitrosating agent like nitrite, and the right conditions of temperature or acidity.
For blood pressure drugs like valsartan and losartan, the contamination traced back to specific manufacturing facilities. During the chemical synthesis of a particular structural component of these drugs (a tetrazole ring), NDMA was generated as a side product. In some cases, contaminated solvents at the factory were the culprit. Once manufacturers identified and corrected these process issues, new batches came out clean.
Ranitidine (Zantac) was a different and more troubling story. The ranitidine molecule itself is chemically unstable in a way that produces NDMA over time. Researchers found that recently manufactured tablets had little to no NDMA, but pills closer to their expiration date contained significantly higher levels. NDMA levels climbed proportionally with time and temperature during storage, and exposure to oxygen accelerated the process. This meant the contamination wasn’t a manufacturing error that could be fixed. It was baked into the chemistry of the drug itself, which is why the FDA ultimately requested that all ranitidine products be pulled from the market in 2020.
Which Medications Were Affected
The FDA has flagged NDMA contamination in several widely used drug classes:
- Ranitidine (Zantac): Withdrawn from the U.S. market entirely due to inherent instability that generates NDMA during storage.
- Valsartan, losartan, and other ARBs: Multiple recalls of specific batches from specific manufacturers. Other batches and brands tested clean.
- Metformin extended-release: Certain lots of the extended-release formulation were recalled. Immediate-release metformin, which is the most commonly prescribed form, has not shown NDMA contamination in FDA testing.
- Varenicline (Chantix): The smoking-cessation drug was recalled due to NDMA levels above acceptable limits.
- Rifampin and rifapentine: Antibiotics used primarily for tuberculosis treatment.
Not every pill in these categories was contaminated. In most cases, the problem was limited to specific manufacturers, specific lots, or specific formulations. The FDA maintains an updated list of recalled products with batch numbers so patients and pharmacists can check specific prescriptions.
How Much NDMA Is Considered Safe
The FDA set an acceptable daily intake limit for NDMA at 96 nanograms per day. That number is based on a calculation: if a person consumed 96 nanograms every single day for 70 years, the theoretical additional cancer risk would be about 1 in 100,000. For context, 96 nanograms is an extraordinarily small amount, roughly a billionth of a gram. When a medication is found to contain NDMA above this threshold, it triggers a recall.
When the acceptable limit can’t be determined through standard testing approaches, the FDA recommends an even more conservative default limit of 26.5 nanograms per day. These limits apply specifically to pharmaceutical impurities. The trace amounts of NDMA people encounter through food and water are regulated separately, though the same carcinogenic concern applies.
What NDMA Does in the Body
NDMA is classified as a probable human carcinogen, meaning animal studies consistently show it causes cancer and the evidence strongly suggests it does the same in humans, though direct human studies are limited for ethical reasons. In animal research, NDMA primarily damages the liver, where it gets metabolized into reactive compounds that can alter DNA. This kind of DNA damage, accumulated over time, is what drives cancer development.
The key factor is long-term, repeated exposure. A single dose of NDMA at the trace levels found in contaminated medications is not considered dangerous. The concern is cumulative: someone who took a contaminated medication daily for months or years would have had a higher total exposure than someone who took it briefly.
What Happens If You Took a Recalled Drug
If you previously took ranitidine, valsartan, or another recalled medication, the realistic risk from NDMA exposure at the levels found in these products is low for most individuals. The 96-nanogram daily limit already includes a large safety margin, and many contaminated batches contained levels only modestly above the threshold rather than dramatically exceeding it.
If you’re currently taking a medication that falls under a recall, the FDA’s guidance is clear: do not stop taking it without talking to your pharmacist or prescriber first. For conditions like type 2 diabetes or high blood pressure, suddenly stopping medication carries its own serious health risks that may outweigh the NDMA concern. Your pharmacist can check whether your specific lot is affected and help you switch to an unaffected version or alternative medication.
How Manufacturers Now Test for NDMA
Since the initial wave of recalls beginning in 2018, the FDA now requires drug manufacturers to evaluate their products for nitrosamine impurities, including NDMA. Companies must assess their manufacturing processes, raw materials, and storage conditions for any risk of NDMA formation. When testing is needed, laboratories use a technique called liquid chromatography with high-resolution mass spectrometry, which can detect NDMA at parts-per-billion levels in finished drug products.
These requirements apply across the pharmaceutical industry, not just to the drugs that were previously recalled. The goal is to catch contamination before products reach pharmacies rather than discovering it after millions of doses have already been dispensed.